For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Black Diamond Therapeutics Inc (NASDAQ: BDTX) closed at $2.94 in the last session, up 2.44% from day before closing price of $2.87. In other words, the price has increased by $2.44 from its previous closing price. On the day, 0.6 million shares were traded. BDTX stock price reached its highest trading level at $3.01 during the session, while it also had its lowest trading level at $2.87.
Ratios:
We take a closer look at BDTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.73 and its Current Ratio is at 8.73. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on September 04, 2025, initiated with a Buy rating and assigned the stock a target price of $8.
On July 31, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $20.Raymond James initiated its Outperform rating on July 31, 2024, with a $20 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 19 ’25 when BIOTECH GROWTH N V sold 5,784,292 shares for $2.07 per share. The transaction valued at 11,997,749 led to the insider holds 2,733,547 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BDTX now has a Market Capitalization of 167389792 and an Enterprise Value of 45312720. As of this moment, Black’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.42. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.76. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.39 while its Price-to-Book (P/B) ratio in mrq is 1.26. Its current Enterprise Value per Revenue stands at 0.647 whereas that against EBITDA is 5.668.
Stock Price History:
The Beta on a monthly basis for BDTX is 3.02, which has changed by -0.48056537 over the last 52 weeks, in comparison to a change of 0.18469036 over the same period for the S&P500. Over the past 52 weeks, BDTX has reached a high of $6.33, while it has fallen to a 52-week low of $1.20. The 50-Day Moving Average of the stock is 6.27%, while the 200-Day Moving Average is calculated to be 30.28%.
Shares Statistics:
According to the various share statistics, BDTX traded on average about 1.02M shares per day over the past 3-months and 695060 shares per day over the past 10 days. A total of 56.89M shares are outstanding, with a floating share count of 43.34M. Insiders hold about 23.88% of the company’s shares, while institutions hold 58.24% stake in the company. Shares short for BDTX as of 1755216000 were 6898065 with a Short Ratio of 6.74, compared to 1752537600 on 6062461. Therefore, it implies a Short% of Shares Outstanding of 6898065 and a Short% of Float of 17.4.
Earnings Estimates
At present, 5.0 analysts are actively evaluating the performance of Black Diamond Therapeutics Inc (BDTX) in the stock market.The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.13 and low estimates of -$0.24.
Analysts are recommending an EPS of between $0.49 and $0.26 for the fiscal current year, implying an average EPS of $0.34. EPS for the following year is -$0.77, with 5.0 analysts recommending between -$0.49 and -$1.04.
